RANBP17 (RAN binding protein 17) is a nuclear transport receptor belonging to the importin-beta superfamily 1. It functions as a key regulator of nucleocytoplasmic transport (NCT), facilitating both protein and transcript cargo movement between the nucleus and cytoplasm 2. RANBP17 interacts with bHLH transcription factor E12 to enhance E2A-mediated transcriptional activity, including upregulation of the cyclin-dependent kinase inhibitor p21 3. Ranbp17 expression declines with age, contributing to age-associated loss of nucleocytoplasmic compartmentalization in human neurons; reduced RanBP17 impairs NCT function in young cells, while restoration rescues NCT in aged cells 4. In DYT1 dystonia, RANBP17 downregulation contributes to compromised NCT and neurodevelopmental deficits; RANBP17 overexpression restores transport function and ameliorates disease phenotypes 2. Ranbp17 variants associate with disease susceptibility, including identification as an HCC-associated gene in rare-variant association studies 5 and as part of a 7-gene prognostic signature in neuroendocrine neoplasms, where mutations correlate with poorer survival 6. Additionally, RANBP17 methylation patterns are altered in response to excessive gestational weight gain and correlate with fetal and neonatal body composition changes 7. These findings establish RANBP17 as critical for maintaining nucleocytoplasmic homeostasis and highlight its relevance in aging and disease pathogenesis.